Compare 3M Company (MMM) vs Nuvalent Inc (NUVL) Price & Performance

3M CompanyTrade

Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

3M Company vs Nuvalent Inc — how do they compare? 3M Company trades at $170.8 (market cap $82.99B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: 3M Company is far larger — about 8.5× Nuvalent Inc's market cap, and 3M Company pays a 1.96% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

	MMM	NUVL
Market Cap	$82.99B	$9.81B
Sector	Industrials	Technology
52-Week High	$174.61	$123.96
52-Week Low	$141.10	$72.16
Enterprise Value	$91.39B	$8.52B
Dividend Yield	1.96%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MMM

3M beats Q2 earnings and raises outlook, driven by growth in optics and industrial segments.Seeking Alpha · 5 hours agoBullish 3M shares jump 10% after beating Q2 earnings and raising full-year EPS forecastGordon Thompson · 7 hours agoBullish 3M shares jump 9% after Q2 earnings beat and raised 2026 guidanceProactive Investors · 12 hours agoBullish View details →

NUVL

Brodsky & Smith investigates fiduciary duty breaches in multiple major merger deals.GlobeNewsWire · 11 hours agoBearish View details →

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.